Clinical Insights: Evolving Paradigms in Metastatic Pancreatic Cancer

Midhun Malla, MD University of Alabama | Michael A. Morse, MD, FACP, MHS Duke Cancer Center | Benjamin Leon Musher, MD Baylor College of Medicine | Janie Y. Zhang, MD University of Pittsburgh Medical Center | Rahul Gosain, MD, MBA Wilmot Cancer Institute | Rohit Gosain, MD Roswell Park Comprehensive Cancer Center

Key Points

• Chemotherapy remains the frontline standard of care for metastatic pancreatic adenocarcinoma, with modified FOLFIRINOX, NALIRIFOX, and gemcitabine plus nab-paclitaxel serving as the primary first-line treatment options.

• Treatment selection should be individualized based on performance status, functional assessment, patient goals, comorbidities, and molecular profiling, with quality of life (QoL) remaining a central consideration in this palliative setting.

• Proactive toxicity management and dose modifications can improve tolerability without significantly compromising efficacy, helping patients remain on treatment longer while minimizing treatment-related adverse events (AEs).

• RAS-targeted therapies represent a promising emerging treatment strategy, but experts emphasized that chemotherapy remains essential and that targeted agents are currently best incorporated through clinical trials or in later-line settings until more data become available.

In a recent Clinical Insight discussion, community oncologists and co-hosts of the Oncology Brothers Podcast, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, were joined by Midhun Malla, MD, of University of Alabama; Michael A. Morse, MD, FACP, MHS, of Duke Cancer Center; Benjamin Leon Musher, MD, of Baylor College of Medicine; and Janie Y. Zhang, MD, University of Pittsburgh, to review current frontline treatment strategies, toxicity management, molecular testing considerations, and the emerging role of RAS-targeted therapies in metastatic pancreatic cancer. The panel emphasized that while new therapeutic options are expanding the treatment landscape, chemotherapy remains the foundation of care for most patients with metastatic disease.

Current Frontline Treatment Options

According to the panelists, frontline treatment decisions for metastatic pancreatic adenocarcinoma currently center around three primary regimens: modified FOLFIRINOX (leucovorin [folinic acid], fluorouracil, irinotecan, and oxaliplatin [mFOLFIRINOX]), NALIRIFOX (liposomal irinotecan, leucovorin, fluorouracil, and oxaliplatin), and gemcitabine plus nab-paclitaxel. Systemic chemotherapy continues to serve as the backbone of treatment, with goals focused on prolonging survival, controlling symptoms, and preserving QoL. The historical development of these regimens stems from landmark studies, including the PRODIGE trial evaluating FOLFIRINOX and the MPACT trial investigating gemcitabine plus nab-paclitaxel.

The approval of NALIRIFOX was driven by results from the phase 3 NAPOLI-3 trial, which demonstrated improved median overall survival (OS) compared with gemcitabine plus nab-paclitaxel. NALIRIFOX achieved a median OS of approximately 11.1 months compared with 9.2 months for the doublet regimen, Dr. Morse said. The trial also showed improvements in progression-free survival, further supporting its use as a frontline option for appropriately selected patients. Despite these advances, treatment selection remains highly individualized. The panel agreed that no single regimen is appropriate for every patient. Factors such as age, performance status, comorbidities, functional independence, and patient goals all play critical roles in determining the most suitable approach.

Patient-Centered Decision-Making and Managing Toxicities

Performance status remains the most important factor guiding treatment selection. Dr. Morse emphasized the value of comprehensive functional assessment, particularly in older adults who represent the majority of patients with metastatic pancreatic cancer. Molecular profiling has also become increasingly important in treatment planning. Universal germline testing and broad next-generation sequencing were strongly endorsed by the panel. Identification of BRCA mutations or other homologous recombination repair abnormalities may influence the use of platinum-based therapies, while emerging molecular targets are expected to play a larger role in future treatment algorithms.

Each frontline regimen carries a distinct toxicity profile. Triplet therapies such as FOLFIRINOX and NALIRIFOX are generally associated with greater gastrointestinal toxicity, including nausea, vomiting, and diarrhea. Gemcitabine plus nab-paclitaxel more commonly causes anemia, fatigue, myalgias, alopecia, and neuropathy. The panel emphasized that toxicity management should begin before treatment starts through proactive supportive care measures, including growth factor support, aggressive antiemetic strategies, and close follow-up during the first treatment cycle.

Dose modification emerged as another important strategy for improving tolerability without sacrificing efficacy. Many oncologists routinely begin treatment at reduced doses and escalate if necessary, Dr. Musher said. Evidence from analyses of NAPOLI-3 suggests that dose adjustments and treatment delays do not necessarily compromise outcomes and may actually help patients remain on therapy longer, supporting a more individualized approach to chemotherapy administration.

Emerging Role of RAS Inhibitors and Future Directions

One of the most anticipated developments in pancreatic cancer is the emergence of RAS-targeted therapies. Dr. Zhang described growing enthusiasm surrounding agents such as daraxonrasib and other investigational RAS inhibitors that are demonstrating encouraging activity in clinical trials. 

The panel cautioned, however, that chemotherapy remains the standard of care and is unlikely to disappear anytime soon. While RAS inhibitors may eventually move into earlier lines of treatment, clinicians emphasized that patients responding well to chemotherapy should continue effective treatment rather than switch prematurely. Toxicities associated with targeted therapies, including significant dermatologic AEs, must also be considered when evaluating these new options.

Looking ahead, experts anticipate a future in which chemotherapy and molecularly targeted therapies are increasingly integrated. Frontline clinical trials are already evaluating chemotherapy–RAS inhibitor combinations, with additional studies exploring earlier use, including in the adjuvant setting. Although metastatic pancreatic adenocarcinoma remains a formidable disease, the panel said that ongoing advances in precision medicine offer renewed optimism for improving outcomes in the years ahead.